Related Experiment Video
Updated: Jul 27, 2026
11:14
Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
Published on: November 7, 2018
Risks associated with hepatitis A and hepatitis B in patients with hepatitis C
1University of Massachusetts Memorial Medical Center, 55 Lake Avenue North, Worcester, MA 01655, USA. koffr@ummhc.org
Journal of Clinical Gastroenterology
|June 22, 2001
Summary
Hepatitis C virus (HCV) patients should receive hepatitis A virus (HAV) and hepatitis B virus (HBV) vaccinations to prevent severe liver disease. Early vaccination is crucial for optimal immune response in individuals with chronic liver conditions.
Area of Science:
- Hepatology
- Vaccinology
- Infectious Diseases
Background:
- Individuals with Hepatitis C Virus (HCV) share risk factors for Hepatitis A Virus (HAV) and Hepatitis B Virus (HBV) infection.
- Superinfection with HAV or HBV can lead to severe hepatitis, hepatic failure, and increased mortality in patients with chronic liver disease.
- Existing data suggest coinfection with HAV and HBV exacerbates liver injury in HCV patients.
Purpose of the Study:
- To review the recommendations and rationale for vaccinating patients with HCV against HAV and HBV.
- To assess the safety and immunogenicity of HAV and HBV vaccines in patients with chronic liver disease.
- To highlight the importance of timely vaccination and the potential benefits of a combination vaccine.
Main Methods:
- Review of current recommendations from health organizations regarding HAV and HBV vaccination in HCV patients.
- Analysis of available data on the clinical outcomes of HAV and HBV superinfections in patients with chronic liver disease.
- Evaluation of the safety and immunogenicity profiles of standard-dose HAV and HBV vaccines in mild-to-moderate liver disease.
- Consideration of emerging data on a combination HAV and HBV vaccine.
Main Results:
- Standard doses of HAV and HBV vaccines are safe and effective in patients with mild-to-moderate HCV or chronic liver disease.
- Vaccination response decreases as liver disease progresses, emphasizing the need for early administration.
- A new combination HAV and HBV vaccine demonstrates comparable safety and efficacy to monovalent vaccines.
Conclusions:
- Routine vaccination against HAV and HBV is recommended for all patients diagnosed with HCV, regardless of disease severity.
- Early vaccination upon HCV diagnosis is critical to maximize vaccine efficacy.
- A combination vaccine offers convenience and may improve compliance among patients with chronic liver disease, warranting targeted healthcare professional outreach.
Related Concept Videos
01:17Transmission-based Precautions I: Contact, Enteric, and Droplets
Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Amebiasis
Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...